A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancerZedao Liu, Chen Chang, Zhenlin Yang et al.|Cell|2025Cited by 103
Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation statusWen‐Zhao Zhong, Yi‐Long Wu|Journal of Hematology & Oncology|2015Cited by 89
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)Chao Zhang, Wen‐Zhao Zhong|Cell Reports Medicine|2024Cited by 31
Expert consensus on treatment for stage III non‐small cell lung cancerYi‐Long Wu, Yun Fan, Yong Song et al.|Medicine Advances|2023Cited by 18
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutationsWenxian Wang, Fan Xia, Bin Lian et al.|The Innovation|2024Cited by 12